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Ever since biomarkers became a primary
tool in epidemiologic studies, the impor-
tance ofvalidating them before using them
in field studies has been stressed (1,2).
Although a few studies have addressed the
issue of sensitivity and specificity of bio-
markers (3-7), no studies have reported
the results ofexperiments aimed at quanti-
fying the sources of variability connected
with the use of biomarkers in human sub-
jects. Estimating the components of vari-
ability provides valuable data for use in the
design of epidemiologic studies. However,
no formal model to study biomarker relia-
bility in humans has been proposed so far.
We have developed several biomarkers
ofexposure to carcinogenic metals, such as
chromium and nickel. In this paper, we
present and analyze data collected from
validation studies carried out on blood
samples from healthy volunteers. Four dif-
ferent biomarkers of exposure are illustrat-
ed: DNA-protein cross-link (DNA-PC),
DNA-amino acid cross-link (DNA-AA),
metallothionein gene expression (MT), and
autoantibodies to oxidized DNA bases
(DNAox). We present a model of valida-
tion developed in our laboratory, the
results of the validation study, and the
impact of estimating the variance compo-
nents on the design of future molecular
epidemiologic studies.
Background
The major components of biomarker vari-
ability that affect the design of epidemio-
logic studies are variability between sub-
jects (intersubject), variability within sub-
jects over time (intrasubject), and variabili-
ty due to assay measurement errors. The
impact ofthese three categories ofvariabili-
ty on the biomarker response can be repre-
sented by a linear model ofthe form:
Yijk = u + aj + b- + ejk
where Y-k is the biomarker response for
subject i on day j and replicate measure-
ment k; u is the true population mean
response; ai is the offset in mean response
for subject i (assumed to be normally dis-
tributed with mean = 0 and variance = s 2;
Sa represents the magnitude ofintersubject
variability); b. is the offset in response on
day j (assumed to be normally distributed
with mean = 0 and variance = Sb; sb rep-
resents the magnitude of intersubject vari-
ability), and ejjk is the assay measurement
error (normally distributed with mean = 0
and variance = se2).
Intersubject variability in biomarker
responses may arise due to factors such as
genetics, race, gender, and diet. Similarly,
the biomarker response for a given subject
may vary over time due to a change in diet,
health status, variations in exposure to the
compounds of interest, and variations in
exposure to other compounds that influ-
ence the biomarker (e.g., tobacco smoke).
Variability in laboratory measurements can
have many sources, some ofwhich will be
specific to a given assay. Two general class-
es of laboratory errors are worth noting:
those that occur between analytical batches
and those that occur within batches.
Analytical variability between batches pre-
sents a special problem in that batch vari-
ability may be superimposed on, and
impossible to separate from, the inter- and
intrasubject components of variability.
Through proper study design, however,
this problem can be minimized.
For a hypothetical molecular epidemi-
ology study involving a comparison ofbio-
marker levels in two populations that dif-
fer in level of exposure to some chemical,
it is generally desirable to minimize the
total intragroup variability. That variabili-
ty represents the weighted sum ofthe three
variance components defined above, with
weights inversely related to the numbers of
subjects, measurements per subject, and
analytical replicates used in the study
design. These design components can be
optimized aprior using information from
a carefully designed validation study ofthe
type discussed below. Once the absolute
and relative magnitudes of the three vari-
ance components are known, a study
design can be determined that minimizes
the total intragroup variance for a given
level ofresources.
Methods
The general scheme for the validation
experiments, illustrated in Table 1,
involves n subjects measured on k occa-
sions, with j replicate samples analyzed on
each occasion. Multiple subjects, occa-
sions, and replicates provide information
on intersubject, intrasubject, and analytical
measurement variability, respectively. The
specific experiment carried out for the dif-
ferent assays, described in detail below,
included one or more components of this
general scheme.
We analyzed data using analysis of
variance methods. For the most general
experimental design (illustrated in Table
1), we used two-way, random-effects
analysis of variance, with subjects and
occasions as the two main effects (8). This
approach provides direct estimates of the
three variance components of interest,
where the variance estimates for the two
main effects correspond to inter- and
intrasubject variability, and the error vari-
ance corresponds to analytical measure-
ment variability.
We applied the model described above
to four biomarkers of exposure to metals.
The validation experiments performed for
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Table 1. General scheme for the experiment of
biomarkers validation
Time (weeks)
Subjects 1 2 3 k
1 11a,b,j 2a,b,j 13a,b,j kab,j
2 21a,b,j 22a,b,i 23abj 2ka,b,j
3 31a~,~ 32aab~J 33a,bj 3ka,b,j
n n1a,b,j n2abj n3abj nka,b,j
aa,b,j = replicates ofthe same specimen at each
time.
each assay are described below. In addi-
tion, a brief description of the assays is
reported here; more technical details are
contained in specific publications cited
throughout the text.
DNA-Protein Cross-link
The DNA-PC method detects the amount
of proteins covalently linked to DNA, a
process that has been implicated in many
aspects ofgene expression and inheritance.
The procedure is applied to frozen white
blood cells and is based on the fact that
sodium dodecyl sulfate (SDS) binds to
proteins but not to DNA. Addition of
potassium chloride to SDS solution results
in the formation ofa potassium-SDS pre-
cipitate which is easily recovered by low-
speed centrifugation. Binding of SDS to
proteins cross-linked to DNA leads to
selective precipitation of DNA containing
a cross-linked protein upon addition of
potassium chloride. The method is
described in detail elsewhere (9).
We recruited five healthy, unexposed
subjects for this study. Blood was drawn
three times in three different weeks. Each
time, the specimens were divided into
three or four aliquots to obtain informa-
tion on laboratory variability on the same
subject. Thus, this experiment followed the
scheme illustrated in Table 1, with n = 5, k
= 3, and] = 3 or 4. We analyzed DNA-PC
at each week, introducing a possible batch
effect that was coincident with weeks.
Amino Acids Cross-linked to DNA
After cellular DNA was purified by stan-
dard proteinase with the phenol procedure,
the residual amino acids associated with
DNA were detected using opthaldialde-
hyde fluorescence. The methods will be
published (10).
As in the previous experiment, five
healthy, unexposed subjects provided
blood samples on three separate weeks,
with laboratory replicates on each occa-
sion. We analyzed specimens each week,
introducing a possible batch effect coinci-
dent with week. Although a total of 14
amino acids were analyzed, we present the
results ofthe variability study on the 7 that
have been demonstrated to increase in
their association with DNA after exposure
to carcinogenic metals such as chromate
(cysteine, histidine, tyrosine, threonine,
methionine, glutamine, and glutamic acid)
(10,11).
Metallothionein Gene Expression
The MT method is aimed at detecting the
level of MT gene expression in peripheral
lymphocytes isolated from whole venous
blood and induced in vitro by treatment
with 1 pM CdCl2 for 1, 3, and 6 hr. MTs
are proteins that form complexes with
toxic metals, and their synthesis is induced
by exposure to metals. We determined
gene induction by isolating mRNA from
the cells followed by standard slot blot
hybridization analysis using a human MT
cDNA probe. The method is described in
detail elsewhere (12).
Four healthy, unexposed subjects were
included in the validation experiment, and
repeated measurements were performed at
four different weeks. We took only one
measurement per subject at each week,
precluding the estimation of analytical
measurement variability from this experi-
ment. Three separate measures ofMT gene
expression were considered: basal level of
MT gene expression and cadmium-
induced gene expression after 2 hr and at 6
hr of treatment in vitro. Variability for
each ofthese measurements was calculated.
Because the experiment required fresh lym-
phocytes, it was performed at each week,
resulting in a potential batch effect that
was considered in the statistical analysis.
Autoantibodies against Oxidized
DNA Bases
The DNAox method measures the amount
ofserum autoantibodies that recognize oxi-
dized DNA bases as a marker ofinflamma-
tory immune response to metals. Antigens
consist ofthe riboside of 5-hydroxymethyl
uracil (HMU) coupled to bovine serum
albumin (HMdU-BSA) and mock-coupled
BSA (M-BSA). Serum is diluted and incu-
bated in the antigen-coated wells; wells are
washed and then incubated with goat anti-
human IgM labeled with horseradish per-
oxidase (HRPO). Addition of H202 and
o-phenylene diamine for HRPO-mediated
oxidation allows the development ofcolor,
which is measured at 492 nm in the
microplate reader. More details are provid-
ed elsewhere (13).
Nine subjects who were part of a
cohort study had blood drawn at three (n
= 3) or four (n = 6) different time points
spanning 1-4 years. Blood samples were
frozen upon collection and stored for later
analysis in one batch. At the time ofanaly-
sis, we analyzed duplicate specimens from
each subject.
Sample Size Calculation
Reliability studies help to determine the
sample size required in a future study. We
hypothesized a classical study of compari-
son between two groups of subjects, one
exposed and one nonexposed to a certain
carcinogen. Ifa certain mean difference, d,
between two groups is considered impor-
tant and a significance level 0.05 and a
95% power is chosen, the number ofsub-
jects per group, n, is calculated as follows:
2(s2T + S e)(Za/2 + Z9)
where (7T + 2e) is an estimator ofthe vari-
ance that will characterize the variability of
single measurements on those subjects, as
provided by the reliability study (8).
Small pilot studies recently conducted
by our group on subjects occupationally or
environmentally exposed to carcinogenic
metals were used to obtain an approximate
value for d, the mean difference between
the two groups. When data were not avail-
able, as for the DNA-AA assay, we consid-
ered a 50% increase of the value observed
among the controls included in this study
to be ofinterest for a future study.
Results
DNA-PC. The analysis ofvariance showed
a significant effect ofbatch variability, but
the intersubject variability was of border-
line significance. A significant interaction
between these two variables was also
observed (Table 2). The interaction can be
interpreted either as evidence that the
batch effect varied across subjects or that
there was additional week-to-week variabil-
ity in DNA-PC beyond that due to the
batch effect. This additional variability
may represent biological variability over
time in individual subject responses.
DNA-AA. Among the amino acids
tested, cysteine and methionine showed a
significant contribution of both batch and
intersubject variability, but no interaction
between them. Threonine showed inter-
subject variability only, and tyrosine
Table 2.Analysis ofvariance on the reliability study: DNA-protein cross-link
Variance component Variance estimate F(df) p
Week 0.0545 13.68(2,7) <0.01
Between subject 0.0176 3.45(4,7) 0,05<p<O.10
Week *subject 0.0110 2.33(7,40) 0.045
Error 0.0317
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Amino acid Variance component Variance estimate F(df) p
Cysteine Week 0.0473 16.72 (2,23) 0.0001
Between subject 0.0078 2.63 (4,23) 0.06
Error 0.0280
Methionine Week 0.0044 5.11 (2,21) 0.02
Between subject 0.0092 6.99(4,21) 0.002
Error 0.0059
Threonine Week 0 <1 ns
Between subject 0.2010 4.69 (4,23) 0.0065
Error 0.3188
Tyrosine Week 0.0413 2.44 (2,14) >0.1
Between subject 0.0193 1.47 (4,14) >0.25
Week* subject 0.0832 7.29 (5,14) 0.0015
Error 0.0271
ns, nonsignificant.
Table 4. Analysis ofvariance on the reliability study: metallothionein gene expression
Variance component Variance estimate F(df) p
Basal Week 0.019 9.00 (3,4) <0.05
Between subject -0.003 0.52 (4,9) ns
Error 0.021
Induced/basal (2 hr) Week 116.34 13.98 (3,4) <0.05
Between subject 2.87 1.34(4,9) ns
Error 27.63
Induced/basal (6 hr) Week 40.95 3.48(3,4) ns
Between subject -8.19 0.75(4,9) ns
Error 105.99
ns, nonsignificant.
Table 5. Analysis ofvariance on the reliability study: DNA oxidative damage
Variance component Variance estimate F(df) p
Between subject 626.97 103.89 (8,23) <0.001
Within subject 14.37 3.12 (23,20) <0.05
Error 11.07
Table 6. Sample size calculation for a future epidemiologic study
Minimum
Assay Variance d sample size'
DNA-PC 0.0603 0.65% DNA(unpublished) 7
Cysteine 0.0766 0.35 nmol AA/mg DNAb 16
Methionine 0.0209 0.1 nmol AAmg DNAb 54
Threonine 0.467 0.9 nmolAA/mg DNAb 29
Tyrosine 0.171 0.5 nmol AA/mg DNAb 18
Metallothionein (induced/basal at6 hr) 155.13 3.5 (unpublished) 329
Metallothionein (basal) 0.043 0.23 (unpublished) 21
Antibodies against oxidized DNA bases 652.41 8.6A492/lJ (14) 38
Abbreviations: DNA-PC, DNA-protein cross-linking; AA, amino acid.
"For each ofthe two groups.
bSince preliminary data are not available, a 50% increase of the value observed among the controls is
considered of interest.
showed interaction between batch and
intersubject variability (Table 3). For histi-
dine, glutamine, and glutamic acid, we did
not detect any significant contribution of
the different components to the variability
ofthe assay.
MT. As shown in Table 4, the batch
effect was more important than between
intersubject variability in basal gene expres-
sion or induced/basal at 2 and 6 hr. To
better understand whether the batch effect
was due to laboratory or intrasubject vari-
ability, we conducted a small experiment
on one subject, whose lymphocytes were
divided into five batches, treated individu-
ally with CdCl2, and analyzed as indepen-
dent samples in the same day by a techni-
cian who was not aware of the nature of
the experiment. The coefficient of varia-
tion of the data was 0.18, showing a low
level ofvariability due to laboratory error
when time was not a factor. The variance
of induced/basal level at 6 hr was 20.7.
From Table 4, the combined effect oflabo-
ratory and intrasubject variability at 6 hr
was 40.7. By comparing the two results,
we can hypothesize that half of that vari-
ance is due to laboratory error, half to
intrasubject variability.
DNAox. Among the different compo-
nents of variance, intersubject variability
was significantly more important than
intrasubject variability (Table 5). No inter-
action was present. The total variance esti-
mated through the experiment described
above was used to calculate the minimum
sample size theoretically required for a
future epidemiologic study including the
same biomarkers used for the reliability
study. Table 6 shows the total variance, the
mean difference between the two groups
considered biologically important, and the
minimum sample size required to detect
that difference.
The calculated sample sizes varied from
329 subjects for MT gene expression to 7
subjects for DNA-PC; a study involving
the use of DNAox would have to include
at least 38 subjects exposed and 38 con-
trols. The other assays require intermediate
values.
Discussion
We have presented a method to validate
the use ofsome biomarkers ofexposure in
human populations by studying the differ-
ent components of their variability. This
step in biomarker validation gives informa-
tion on whether the biomarker is suitable
for epidemiologic studies. In fact, even in
the presence ofacceptable laboratory sensi-
tivity and specificity of a given biomarker,
the excess ofintraindividual and laboratory
variability observed in healthy volunteers
might make its use in human studies not
feasible. For example, in our experiment
we observed a high level of variability in
induced/basal levels of MT gene expres-
sion, mainly due to a temporal effect that
might be ascribed to both intraindividual
and batch variability. Unfortunately,
efforts to reduce these sources ofvariability
have been unsuccessful to date, perhaps
due to the nature ofthe experiment, which
involved fresh lymphocytes grown and
stimulated in vitro. However, basal levels
of MT gene expression exhibit a small
amount ofvariability, therefore their use in
epidemiologic studies should be considered
more promising than the induced levels of
gene expression.
DNA-PC showed a significant batch
effect and a significant interaction between
subjects and batch. The latter may be inter-
preted in two ways: as an indication that
the batch effect varies across subjects, or
that there is significant intrasubject variabil-
ity over time due to biological factors. In
the present context, none ofthese possibili-
ties can be substantiated or rejected.
However, to avoid the laboratory batch
effect in future work, the assay has been
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modified so that isolated lymphocytes are
now frozen and the detection of DNA-PC
is performed later, in one single experiment.
The examples reported show how the
analysis of biomarker variability can be
used by both the epidemiologist to design
a new study, and the molecular biologist to
technically improve the assay. A validation
study such as the one we conducted can
detect the amount ofvariability ofthe bio-
marker present in healthy subjects and pre-
sumably variability expected in a field
study involving exposed populations and
controls; this information can be used by
the epidemiologist to calculate the sample
size required for future studies. Calculating
sample size is extremely helpful, especially
when different biomarkers are tested in the
same study. This happens more and more
often in order to optimize the use ofavail-
able resources and to improve the under-
standing ofbiological mechanisms (1). We
may hypothesize that the biomarkers
described in our paper will be included in a
single epidemiologic study as markers of
exposure to carcinogenic metals. In this
case, a sample size that can be sufficient to
detect a significant difference in DNA-PC
between exposed and controls may not be
adequate when using an assay showing a
great amount ofbiological variability, such
as induced levels MT gene expression.
In conclusion, we propose that the lab-
oratory development of a new biomarker
should be followed by small-scale studies
on healthy volunteers to assess intra- and
interindividual variability and laboratory
error. We demonstrated that the same
design can be used by different laborato-
ries, with small modifications. The results
can be helpful to improve the biomarker
reliability and to plan future epidemiologic
studies.
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